Overwatch Imaging Awarded Phase II SBIR by the U.S. Navy
By reducing reliance on human operators to perform repetitive and focus intensive EO/IR functions, this solution will accelerate the flow of actionable intelligence while freeing operators to focus on more complex situational awareness and decision-making.
Share
Under the two-year Phase II effort, Overwatch Imaging will deliver a solution to automate sensor control, real-time AI-based image analysis, data-reduced intelligence packaging, and seamless integration with USN mission systems. The project will provide capabilities compatible across all USN aircraft that lower operator workloads, utilize existing systems and data, increase speed of intelligence delivery, and provide real-time situational awareness to tactical and strategic leadership.
This solution will build on Overwatch Imaging's commercially available Automated Sensor Operator (ASO) software, expanding it for USN-specific, joint, and U. S. Coast Guard mission contexts and operational environments.
The U.S. Navy published its Priority Technology Areas in a June memo with a goal of 'accelerating the adoption of emerging technologies that will allow us to outpace adversaries and ensure readiness in an unpredictable world.'
The first priority listed in the memo is AI / Autonomy, which is noted as capable of 'enabling decision advantage and enhancing the ability of human-machine teaming.' Specifically, the AI / Autonomy Level 1 priority is for 'AI-driven solutions for real-time data analysis and automated decision-making to enhance operational effectiveness.'
This work is perfectly aligned with the Navy's technology priority as it enables seamless integration of AI / Autonomy into its existing and new imaging systems, in time to make a difference against current and emerging threats.
'This award represents an important step forward in our efforts to deliver a scalable, mission-ready solution for Naval operations facing time-critical detection challenges,' said Greg Davis, Founder and CEO of Overwatch Imaging. 'By reducing reliance on human operators to perform repetitive and focus intensive EO/IR functions, this solution will accelerate the flow of actionable intelligence while freeing operators to focus on more complex situational awareness and decision-making tasks.'
This award follows a successful Phase I research effort and reinforces Overwatch Imaging's role as a key innovator in defense-oriented autonomous intelligence, surveillance and reconnaissance (ISR) solutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Cabinet approves Phase-1B of Lucknow Metro Rail Project with Rs 5,801 crore outlay
By Aditya Bhagchandani Published on August 12, 2025, 16:21 IST The Union Cabinet, chaired by Prime Minister Narendra Modi, has approved Phase-1B of the Lucknow Metro Rail Project in Uttar Pradesh. This phase will cover 11.165 km and include 12 stations — 7 underground and 5 elevated — with a total project outlay of Rs 5,801 crore. Once operational, Lucknow's metro network will expand to 34 km. The new corridor aims to improve public transport in Old Lucknow, covering key commercial areas like Aminabad, Yahiyaganj, Pandeyganj, and Chowk, along with major healthcare facilities such as King George's Medical University. The route will also connect popular tourist attractions, including Bara Imambara, Chota Imambara, Bhool Bhulaiya, Clock Tower, and Rumi Darwaza, as well as renowned culinary destinations. Phase-1B is expected to significantly reduce traffic congestion on heavily crowded roads, cut travel times, and improve road safety. Environmentally, the expansion will help reduce carbon emissions by providing a sustainable alternative to fossil fuel-based transport. The government anticipates the project will spur economic growth by improving access to workplaces, railway stations, bus depots, and the airport. It is also expected to boost local businesses, attract investment, and enhance tourism. Additionally, the expansion will provide equitable access to transport for diverse socio-economic groups, improving overall quality of life for city residents. The Phase-1B project is seen as a transformative step for Lucknow, addressing urban mobility challenges while laying the foundation for future metro expansions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Associated Press
3 days ago
- Associated Press
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]
Yahoo
6 days ago
- Yahoo
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...
Release Date: August 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Vistagen Therapeutics Inc (NASDAQ:VTGN) is advancing its lead product candidate, intranasal facidiol, through late phase 3 development for the acute treatment of social anxiety disorder (SAD), addressing a significant unmet need. The company expects to report top-line data from its Palisade 3 phase 3 trial in Q4 2025, which could be a critical value inflection point. Vistagen is also advancing its KOL outreach and planning further phase 2 development for other product candidates targeting major depressive disorder and menopausal hot flashes. The company has a strong cash position with $63.2 million in cash equivalents and marketable securities as of June 30, 2025. Vistagen has enhanced its study protocols and eligibility criteria, which are expected to improve the quality and reliability of trial outcomes. Negative Points Research and development expenses increased significantly to $11.7 million from $7.6 million year-over-year, reflecting higher investment in clinical programs. The net loss attributable to common stockholders widened to $15.1 million compared to $10.7 million in the same period last year. There are ongoing risks and uncertainties associated with the forward-looking statements and clinical trial outcomes. The company had to terminate a clinical trial site in Pennsylvania due to issues with site conduct and enrollment challenges. Vistagen faces competition from other companies, such as Euphoria (formerly Bionomics), which is also conducting phase 3 trials for SAD. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with VTGN. Q: Do you still plan to announce when you complete enrollment for the study, and if so, any estimation of when that could possibly be? Also, any commentary on dropouts or retention? A: Yes, we will announce the Last Patient Out (LPO). We are sticking with guidance that we'll see Top Line Results (TLR) in Q4. Regarding the Open Label Extension (OLE), we've seen encouraging conversion rates from the randomized study into the OLE, with over 80% of subjects moving into the open label and good retention rates. This supports our assumptions for total exposures, especially the 6 and 12-month requirements. - Sean Singh, CEO, and Josh Prince, COO. Q: In the top line data in Q4, what do you envision sharing in your press release and company slides? Will you include efficacy kinetics over time and secondary endpoints? A: We will share similar information to what we provided for Palisade 2, focusing on primary and secondary endpoints. In Palisade 3 and 4, PGICs are secondary endpoints, and we will remark on those. We expect to see similar efficacy between male and female participants, as we did not see statistically significant differences in Palisade 2. - Sean Singh, CEO. Q: Can you comment on the enrollment status of Palisade 4 and whether there is room to adjust the trial design based on results from Palisade 3? A: Both Palisade 3 and 4 are currently enrolling. We do not anticipate any adjustments to the protocols as we have built in additional enhancements and rigor. The staggered start helps with training and oversight, and we are leveraging best practices across both studies. - Sean Singh, CEO, and Josh Prince, COO. Q: What do you measure in the open label phase besides safety? A: Besides safety, we capture the patient withdrawal checklist to demonstrate non-addictive qualities and measure the Liebowitz Social Anxiety Scale (LSAS) monthly. This scale assesses the severity of social anxiety disorder over time, and we have seen encouraging drops in LSAS scores in previous studies, indicating potential long-term benefits. - Josh Prince, COO. Q: Regarding the recent termination of a trial site in Pennsylvania, what were the reasons behind this decision? A: The decision to terminate a site can be due to various reasons, including site conduct, enrollment issues, or staff turnover. We maintain constant dialogue with sites and provide retraining if necessary. However, if a site cannot execute the study or provide the required enrollment, it may be terminated. - Josh Prince, COO. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
